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Neglect of Plasmodium vivax malaria
J. Kevin Baird
ALERTAsia Foundation, Jalan Diponegoro No.69, Menteng, Jakarta, Pusat 10430, Indonesia

Plasmodium vivax infects 130–435 million of the 2.6
billion people living at risk of infection. Recent studies
suggest that vivax malaria can become lethal in a similar
way to severe falciparum malaria. First-line therapies
remain unchanged after 50 years. Despite evidence of
failing chloroquine efficacy, little work has assessed the
problem or explored alternative therapies. Primaquine
treatment, the only therapeutic option against relapse,
might also be failing. No licensed primary chemoprophylactic agent protects travelers from relapse. Misdiagnosis of species now affects clinical decisions resulting
in inadequate therapy for P. falciparum and P. vivax. All
of these factors demonstrate the lack of research on
P. vivax.
Investment and therapeutic options
Research investments reach across a broad spectrum of
inquiry into the physiological, clinical, social and economic
consequences of infectious disease burdens, as well as their
treatment, prevention and control. Successful clinical management of potentially dangerous and prevalent infections
surely represents the highest research priority. This
review treats research on therapies as the principal
indicator of broader research investments.
The quality of available therapies for dangerous
infections reflects investments made in research on these
diseases. The quality of therapy can be defined as the
reliability of carefully analyzed clinical research demonstrating good safety, tolerability, efficacy and effectiveness.
An even higher standard of quality provides understanding of metabolism, mechanisms of both therapeutic action
and toxic side effects, and mechanisms of resistance by
the target organisms. These facets of quality allow us to
move forward with better therapies and, in turn, provide
clinicians with options and a basis for making sound
therapeutic management decisions. In other words, the
hallmarks of infections that have received adequate attention and investment in research are the availability of
drugs of predictable performance and of therapeutic
options in the face of predictable or realized failure.
Against this backdrop Plasmodium vivax might be
considered perhaps the most neglected, potentially dangerous and highly prevalent infection. The two current frontline therapies for P. vivax, chloroquine (CQ) and primaquine
(PQ), have been in use since 1946 and 1950, respectively.
These therapies are failing, but the risk of failure with either
drug is not generally known. The mechanism of activity of
either drug and the mechanisms of resistance remain
unknown. The metabolism of PQ is little understood.
Corresponding author: Baird, J.K. (kbaird@alertasia.org).
www.sciencedirect.com

PQ destroys red blood cells with an inborn deficiency of
glucose-6-phosphate dehydrogenase (G6PD) – a disorder
linked with endemic malaria and most prevalent where
the drug is most needed – but the mechanism of toxicity
or the metabolite responsible for it is unknown. There are
some poorly characterized alternatives for CQ, and none for
PQ. The strikingly poor quality of drugs available to treat
vivax malaria reflects a lack of research investment in this
infection.
If the marker of quality of therapeutics is applied to P.
falciparum, the far more substantial investment in
research on this parasite is evident. The past ten years
have seen a much-needed and overdue proliferation of
well-characterized therapeutic options for falciparum
malaria. No one can argue against the higher research
priority placed upon falciparum malaria therapies, given
its greater lethality and perhaps prevalence. However,
seeing the investment in treatment of falciparum malaria
as directly linked and applicable to the problem of therapy
of vivax malaria does not stand scrutiny. No fact supports
this argument more clearly than the current state of
therapeutic options for vivax malaria, which is detailed
in this review.
A highly prevalent and potentially dangerous
infection
Diseases that are highly prevalent but benign or dangerous
but exceedingly rare can reasonably merit little research
investment. However, Plasmodium vivax is neither rare
nor benign. It occurs throughout the tropics, except in
western and central sub-Saharan Africa where the absence
of Duffy factor on the surface of red blood cells largely
protects those populations. Guerra et al. [1] recently
reported estimates of people living at risk of falciparum
and vivax malaria at 2.5 and 2.6 billion people, respectively. Hay et al. [2] estimated 130–435 million infections by
P. vivax, in contrast to the more widely cited figure of 70–80
million annual infections [3]. At even the lower estimate,
this roughly equals the disease burden of dengue fever and
exceeds the disease burden of typhoid by about fivefold.
It has long been considered that vivax malaria is rarely
fatal, and if it is fatal, it is considered to almost always be a
consequence of rupture of the spleen [4]. Few texts attribute to P. vivax the syndromes occurring in severe and
complicated P. falciparum malaria. However, recent studies using PCR diagnostic technologies revealed that
patients diagnosed with vivax malaria and having cerebral
malaria, acute respiratory distress syndrome (ARDS), liver
dysfunction and renal failure had no evidence of falciparum malaria [5–8]. Table 1 summarizes 108 cases of
severe and complicated vivax malaria since 1998, 17 of
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Table 1. Reports of severe and complicated P. vivax malaria since 1998
Location
India

Year
2003

No. of cases
11
adults

Pakistan
Venezuela
India
Afghanistan
Singapore
Columbia
Malaysia

2000
2005
2006
2004
2003
1998
2003

1
1
1
1
2
1
2

India
India
Turkey
Indonesia

1999
2002
2005
2000

2
16
1 child
21 children
17 adults

Afghanistan
India

2003
2000

1 adult
22

Brazil
New Guinea
India
Kenya
Turkey
India
India
Total

2000
2000
1998
2004
2003
2002
2006

1
1
1
1
2
1
1

adult
adult
adult
adult
adults
adult
adults

adult
adult
adult
adult
adults
adult
child

Presentation
Renal failure = 4
Jaundice = 4
ARDS = 3 (1 fatal)
Cerebral = 3 (1 fatal)
Cerebral
ARDS
ARDS
ARDS
ARDS (fatal)
ARDS
ARDS = 1
DICa/Renal Failure = 1 (fatal)
Renal failure = 2
Renal failure = 16
Convulsions
Cerebral = 3 (2 fatal)
Siezures = 2 (1 fatal)
Anemia = 24
Hyperparasitemia = 1
Renal failure = 4
Liver dysfunction = 10 (3 fatal)
Acidosis = 3 (1 fatal)
ARDS = 2 (1 fatal)
Cardiac arrest = 1 (fatal)
ARDS
Liver dysfunction = 8
Cerebral = 1 (fatal)
Anemia = 8
Thrombocytopenia = 4
Pancytopenia = 1
Thrombocytopenia
ARDS
Thrombocytopenia
Splenic rupture
Splenic rupture
ARDS
Renal failure

Fatal cases
2

Refs
[5]

0
0
0
0
1
0
1

[6]
[7]
[8]
[9]
[10]
[11]
[12]

?
3
0
9

[13]
[14]
[15]
[16]

0
1

[17]
[18]

0
0
0
0
0
0
0
17

[19]
[20]
[21]
[22]
[23]
[24]
[25]

a

DIC, disseminated intravascular coagulation.

which proved fatal [5–25], and only two reports of a total of
three patients with ruptured spleens, who all survived
[22,23]. A 2004 review of the literature [23] reports that
only 11 well-documented cases of splenic rupture in vivax
malaria were published in the English medical literature
since 1960. Ruptured spleen is either tremendously underrepresented in the medical literature, or it is a minor
contributor to the spectrum of severe disease caused by
vivax malaria. A recent report by Anstey et al. [26]
describes lung injury among 50 patients with vivax
malaria, and these authors report findings suggestive of
parasite adhesion within pulmonary microvasculature.
A retrospective analysis of nearly 6000 hospital
admissions for malaria over three years at Jayapura in
Papua, Indonesia revealed that a third of patients had a
diagnosis of P. vivax (two-thirds of those with monoinfections) by microscopy [16]. In that setting, almost all diagnosed malaria was managed on an outpatient basis, and
only the significantly ill were admitted. Among the 1135
patients admitted with a diagnosis of vivax malaria, 38
were classified as having severe malaria (predominantly
cerebral malaria), ARDS, liver dysfunction or renal failure.
The 25% case fatality rate with a diagnosis of vivax malaria
and a classification of severe disease was identical to those
among similar patients with falciparum malaria [16].
www.sciencedirect.com

Ruptured spleen was not reported in any of the patients
at Jayapura, despite 1952 admissions with a diagnosis of
P. vivax (including 817 mixed infection diagnoses). Syndromes more closely resembling severe and complicated
falciparum malaria dominated presentations of severe
disease among patients with a microscopic diagnosis of
vivax malaria.
All of the reports of severe and complicated vivax
malaria described in Table 1 apart from five [5–8,11] lack
evidence ruling out cryptic falciparum malaria or inaccurate microscopic diagnoses. Clinicians and laboratory
workers managing severely ill patients in endemic areas
rarely have the advantage of PCR diagnostics, and presentation of cerebral malaria, ARDS, liver dysfunction and
renal failure often leads to the presumptive diagnosis of
severe falciparum malaria. Even if the microscopist
reports a parasitemia of P. vivax, the absence of P. falciparum in the smear might be dismissed either as a lack
of expertise at the microscope (mixed infections are
notoriously difficult to detect) or as sequestration of
P. falciparum. The investigators for most of the reports
summarized in Table 1 apparently overcame this bias and
reported vivax malaria as the causative agent. Prospective
studies using PCR diagnostics of severely ill malaria
patients are required to gauge the true risk of severe
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and fatal disease with vivax malaria. Perhaps more
importantly, such studies must also rule out other infections likely to occur in a given area, for example bacterial
meningitis, typhus, leptospirosis and dengue.
Well-documented studies reinforce the perception that
vivax malaria is a relatively benign infection. Vivax
malaria has been thoroughly studied in the clinical
setting, albeit most often with a narrow range of strains
represented, along with prompt diagnosis and treatment
precluding serious disease [27,28]. Moreover, deaths due to
P. vivax malaria among travelers occur rarely compared
with those due to P. falciparum [29–31]. Finally, epidemic
P. falciparum carries the well-known risk of high
mortality, but there is no such record for epidemic P. vivax.
Most of what is known about morbidity and mortality
linked to vivax malaria does not address settings of chronic
and perhaps inadequately treated P. vivax malaria. Prevalent underlying disease states, like coinfections and nutritional deficiencies, add further uncertainty. The available
data on severe P. vivax malaria suggest that there are
conditions in which this parasite becomes lethal in a
manner strikingly similar to that of P. falciparum. Many
of the patients included in Table 1 come from settings
where repeated exposures and relapse are likely, as well
as risk for coinfection and poor nutrition. In the specific
instance of the island of New Guinea, dominant resistance
to CQ and to PQ (see below) may contribute to risk of severe
disease.
The perception of vivax malaria as relatively benign
may stem not only from an incomplete representation of
settings of infection and disease, but perhaps also from an
incomplete understanding of the taxonomy of the species.
Some workers suggest that P. vivax is a complex of
species [32]. Studies of naturally occurring morbidity
and mortality caused by chronic exposure, inadequate
therapy and relapse need to be done, particularly those
supported with autopsy findings and thorough investigation of parasite genotypes.
Failing chloroquine therapy
Chloroquine has been first-line therapy for P. vivax since
1946. Although as little as 0.3 g CQ routinely cured CQsensitive P. vivax, the experts made no distinction between
P. vivax and P. falciparum in recommending 1.5 g total
adult dose for treatment of acute attacks of malaria [33].
This might, in part, explain the relatively late first-known
appearance of CQ-resistant P. vivax in 1989 from Papua
New Guinea [34]. The exquisite sensitivity of gametocytes
of P. vivax to CQ (and the absence of such sensitivity in
P. falciparum) might also help explain the prolonged effectiveness.
Studies in eastern Indonesia during the 1990s revealed
a severe CQ resistance problem, with most treatments
ending in failure [33]. More recent studies in eastern
Indonesia reported essentially similar findings [35]. Surveys elsewhere in Indonesia showed low risk of failure in
the western provinces and intermediate risk towards the
center of the archipelago [33]. Case reports of resistance
appeared from other countries in the region [33]. However,
sustained survey work measuring risk of CQ failure in
vivax malaria has been done only in Indonesia, Thailand
www.sciencedirect.com
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and India. In Thailand, a thorough examination of several
thousand infections revealed almost no evidence of resistance [36–40]. Among 869 subjects evaluated in three separate studies in India, none showed evidence of resistance
to CQ [41–43]. Survey work in Turkey [44,45] and in
Vietnam [46] showed moderate levels of resistance (15%
and 22% failure, respectively). A recent study in northeastern Indonesian New Guinea, where failure for CQ
alone approaches 100%, showed only 18% failure when
CQ was supplemented with PQ [47]. Surveys from South
America show from no resistance to low levels of resistance
[48,49]. The problem of CQ-resistant P. vivax thus appears
to have originated on the island of New Guinea and might
be spreading outwards, but not yet within the reach of
Thailand or India (see Table 2).
The reporting of systematic surveys to gauge the risk of
CQ failure cannot be considered adequate in any region,
including southeast Asia, and information from other
regions is limited to only a few case reports – relatively
little such risk assessment work appears to be in progress.
Despite compelling evidence of failing efficacy, almost no
research is under way to ascertain the risk of therapeutic
failure of the first-line therapy for a potentially lethal
infection that threatens 2.6 billion people.
Effective therapies for chloroquine-resistant P. vivax
A few reports describe the efficacy of approved drugs for
the treatment of P. vivax [50–53], and some reports
describe treatments for CQ-resistant P. vivax [54–56].
Mefloquine (MQ) combined with PQ was effective in
Papua, Indonesia (98% efficacy) [47], and CQ combined
with PQ was much more effective than CQ alone [47,54].
Some work in primate models also showed good efficacy of
both MQ and the experimental 8-aminoquinoline, tafenoquine [57–59]. The failure to achieve continuous culture of
P. vivax severely constrains the investigation of effective
therapies, leaving clinical trials in humans and primate models as the only options for exploring alternatives.
The expense and risk of such work usually requires solid
preclinical studies as a foundation. Recent improvements
with in vitro assays of drug activity against P. vivax (a rare
example of a significant advance in research on this parasite) [60–63] at least offer the means of investigation of
therapies in which the parasite can be obtained with
relative ease. Despite evidence of resistance to CQ, and
a reasonable forecast of further deterioration, clinical
investigation of alternative treatments for vivax malaria
resistant to CQ rarely occurs.
The puzzle of primaquine therapy
No standard drug for an infection can be more shrouded in
mystery than PQ. Despite more than 50 years of continuous use in millions of people annually as the only drug
available for its therapeutic indication, it is not known how
PQ acts, how it should be taken, or if it acts when taken as
directed [64].
PQ generates a complex mix of metabolites, each
exhibiting often sharply distinct chemical and biological
activities [65]. Which of these metabolites actually occur in
the human liver and participate in killing hypnozoites, and
how, is not clear. Nor is it clear which metabolites account
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Table 2. Surveys for chloroquine-resistant P. vivax since 2000
Location
Indonesia
Turkey
Indonesia a
Vietnam
Turkey
Peru
India
Thailand a
India a
Colombia a
Thailand
India

Year
2004
2004
2000
2001
2001
2001
2004
2004
2004
2004
2003
2001

Subjects (n)
40
91
60
113
112
177
287
31
102
210
161
480

Resistant (%)
65
22
18
16
15
2
0
0
0
0
0
0

Refs
[35]
[44]
[47]
[46]
[45]
[48]
[41]
[39]
[42]
[49]
[39]
[43]

certainly prevents the formation of hypnozoites rather
than kills them.
The efficacy of PQ for preventing relapse is not
understood. Definitive experimental challenge trials evaluating this activity have not been done in over 50 years.
There is no widely accepted method for measuring the
efficacy of PQ in clinical trials, and such measurements
present onerous technical, logistical and ethical barriers.
Except for a few rare exceptions, the trials are not done. PQ
is the only drug available for preventing debilitating and
possibly lethal relapses, and it is not known whether PQ is
effective.

a

Chloroquine combined with primaquine (greater efficacy).

for the hemolytic toxicity of the drug to people with G6PD
deficiency. The largely hypothetical 6-methoxy metabolites
of PQ do exhibit relatively strong activity against P. berghei liver stages [66], and when present in an environment
favoring oxidized species (like redox-challenged G6PDdeficient red blood cell cytoplasm) become potentially toxic
membrane disruptors [67,68].
Setting aside the unknowns of metabolism, the
pharmacokinetics of PQ is fairly well understood [69]. It
is highly water soluble, rapidly absorbed and almost completely eliminated within 24 h. Its peak plasma levels
occur within just an hour or two, and plasma levels drop
by a half within two hours. The pharmacokinetic profile of a
standard 14 day regimen resembles uniform fence posts –
14 independent spikes of presumably therapeutic levels of
the drug. Preclinical and clinical studies revealed something unusual about these spikes – the sum of the areas
under the curves (total dose) determined therapeutic efficacy independently of the dosing schedule [64,70]. If the
daily dose of PQ is doubled and given for only 7 days, then it
is equally effective. A 1.5-strength dose administered
weekly over 8 weeks is effective too. As long as the sum
length of the height of the ‘fence posts’ is the same (i.e. total
dose), their individual height or space between them does
not seem to affect the efficacy. The effect of PQ on the
parasite seems to be cumulative. The mystery of this
phenomenon almost certainly lies in our almost complete
lack of understanding of the physiology of hypnozoites.
A series of clinical trials in the 1950s reported findings
that challenged the notion that PQ is effective at all when
given as monotherapy [71,72]. When challenged with sporozoites of the Chesson strain, volunteers were given either
210 or 315 mg PQ, either concurrently with standard CQ or
quinine (QN) therapy, or after completing QN therapy. In
effect, the investigators used combined therapy (CQ plus
PQ or QN plus PQ) or two independent monotherapies (QN
followed by PQ). At both of the total doses of PQ, QN
therapy followed by PQ resulted in 80% relapse rates,
whereas the combined therapies gave essentially effective
cures. The participation of QN and CQ in the activity of PQ
seems the most likely explanation for these findings, even
though neither drug has any known effect on liver stages
when given as monotherapy against blood stages. PQ
might require a companion drug to prevent relapse by
P. vivax. The good efficacy of PQ alone as a causal prophylactic [73,74] does not necessarily run counter to this
evidence – daily PQ for primary prophylaxis almost
www.sciencedirect.com

Preventing P. vivax
Every randomized, placebo-controlled trial of drugs for the
prevention of malaria in travelers in the past 20 years has
failed to address efficacy against late relapse by P. vivax.
These trials tend to focus on demonstrating efficacy against
P. falciparum while traveling. Indeed, study subjects are
almost always residents of highly endemic areas, a fact
driven by sample size and attack rate issues. The effect on
late relapse is often deemed a separate issue covered by the
practice of terminal prophylaxis with PQ, that is, presumptive standard therapy immediately following exposure
(synonymous with post-exposure treatment or PET) [74].
Separating these issues has practical validity; however,
one gets back to the issue of whether the presumptive
therapy provides protection against relapsing vivax
malaria in travelers. Schwartz and colleagues [75,76]
looked at the effectiveness of various regimens of prophylaxis in Israeli travelers. Suppressive prophylaxis (the
standards such as MQ or doxycycline) routinely failed to
prevent late relapses of P. vivax, despite the prescribed use
of PQ terminal prophylaxis. PQ as primary prophylaxis
might be the only tool available that protects travelers
from vivax malaria. Although now recommended by the US
Centers for Disease Control and Prevention (CDC) and
similar agencies of other governments, the current US
registered label for PQ does not include an indication for
this use [74]. Despite significant risk of P. vivax relapse
among travelers, no currently approved drug or combination of drugs is known to be effective in preventing this
risk. The only drug known to be effective, PQ, is not
licensed for this use.
Correct diagnosis of P. vivax
The successful development and distribution of the
artemisinin-based combined therapies (ACT) for treatment of P. falciparum and the almost universal continuing
use of CQ for vivax malaria create an important need for
reliable diagnostic methods. Patients who have P. falciparum malaria that is diagnosed as vivax malaria might
receive ineffective therapy. The health or even life of a
patient might hinge upon the competency of the microscopist making the diagnosis.
Diagnosis of malaria by microscopy has been almost
completely neglected since the heyday of the Global Eradication Campaign. Most microscopists working in clinics,
hospitals and even research institutions received their
training in school, and perhaps have been through
refresher training. However, there is no standard method
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for measuring the competency of microscopists. In the field,
the reliability of microscopists is usually measured by age
and experience, simply because no other useful metric
exists.
How often is P. falciparum misdiagnosed as P. vivax? The
risk of a potentially grave error appears high even for expert
microscopists. Mayxay et al. [77] found 8% of P. vivaxinfected Thai patients in Bangkok treated with CQ later
developed falciparum malaria. Studies in Asia and the
Americas typically report 13%–19% of microscopically
P. vivax-positive specimens also contained P. falciparum
detected by PCR assay [78]. Among well-trained clinical
malaria microscopists in Thailand, 61 of 446 (14%) true
P. falciparum infections were diagnosed as P. vivax malaria
[79]. During refresher training of 223 practising microscopists in Indonesia over 15 years, the error rate for species
diagnosis of P. falciparum was 23% (K.B., unpublished).
In the setting of CQ-resistant P. falciparum, these error
rates might estimate the risk of inappropriate therapy.
Rapid diagnostic tests (RDT) do not solve this problem
either. The risk of false negative P. falciparum with RDT
(varying from 2% at >5000 parasites mL 1 to 25% at <500
parasites mL 1 [80]) can be considered the risk of receiving
ineffective chloroquine therapy where P. vivax, P. malariae
or P. ovale also occur.
Concluding remarks
Several key factors have contributed to the neglect of vivax
malaria in research. Until very recently, the global burden
of disease has almost certainly been underestimated by a
very large margin [2,3]. The broadly held perception of
vivax malaria as a benign infection diminished its standing
with regard to research priorities. Finally, the inability to
maintain P. vivax in continuous culture in vitro undoubtedly hindered research in the laboratory, and forced most
research investments into relatively inaccessible, costly
and difficult endeavors in endemic areas.
The highlighted gaps in understanding put forth in this
review represent front-line research questions (Box 1).
Although expanding laboratory work and interest would
undoubtedly yield valuable tools against vivax malaria,
the urgent need is for clinical and epidemiological studies.
Box 1. Oustanding questions for P. vivax research
Is P. vivax a complex of species?
Does P. vivax cause a falciparum-like severe illness syndrome?
Does P. vivax have virulent strains?
What are the demographic or clinical risk factors for severe disease?
What is the mechanism of chloroquine activity?
How widespread is resistance to chloroquine?
What is the mechanism of resistance to chloroquine?
What are effective alternative therapies for chloroquine-resistant
strains?
What is the mechanism of primaquine activity against hypnozoites?
Is primaquine monotherapy effective against hypnozoites?
What is the mechanism of primaquine toxicity in G6PD deficiency?
How can G6PD deficiency be determined at the point of care?
How widespread is resistance to primaquine?
How should resistance to primaquine be documented?
What is the mechanism of resistance to primaquine?
What are effective alternative therapies against relapse?
How can late relapse in travelers be prevented?
How can P. vivax be diagnosed accurately?
www.sciencedirect.com
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Those studies would give greater direction and impact to
laboratory studies. Grasping when, how and how often
vivax malaria causes severe illness and what drugs most
effectively cure the severely ill, represent the first important steps in addressing the neglect of this parasite.
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